Translocational renal cell carcinoma (t(6;11)(p21;q12) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report

Journal of Medical Case Reports

Eivind Hovig⁵  Mona-Elisabeth Revheim²  Leonardo A. Meza-Zepeda³  Ljiljana Vlatkovic¹  Wolfgang Lilleby⁴ 

[1] Department of Pathology, Oslo University Hospital, Nydalen, Oslo, 0424, Norway;Department of Radiology and Nuclear Medicine, Oslo University Hospital, Nydalen, Oslo, 0424, Norway;Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Nydalen, Oslo, 0424, Norway;Department of Oncology, Oslo University Hospital, Nydalen, Oslo, 0424, Norway;Department of Informatics, University of Oslo, Blindern, Oslo, 0316, Norway

关键词: Translocation renal cell carcinoma;    Gene signature;    Autophagy;   

Others  :  1235856
DOI  :  10.1186/s13256-015-0749-7

 received in 2015-02-20, accepted in 2015-10-26,  发布年份 2015

【 摘 要 】

Introduction

Renal cell carcinoma with the distinct type of t(6;11)(p21;q12) translocation (transcription factor EB) is a rare neoplasm. In the present case study, we show for the first time an autophagy signature in a patient with transcription factor EB renal cell carcinoma. We attempted to characterize the mutational and expressional features of a t(6;11)(p21;q12) renal cell carcinoma, in an effort to address the potential for molecular guidance of personalized medical decision for a case in this renal cell carcinoma category.

Case presentation

We report the case of a 42-year-old white man who had a late relapse of his renal cell carcinoma. The first diagnosis of clear cell renal carcinoma was derived from a histological examination; analyzing the metastasis and going back to the primary tumor it turned out to be a transcription factor EB-renal cell carcinoma. The treatment plan included local radiation and systemic therapy. As part of the multimodal approach, tumor samples for genetic assessment were obtained. However, there is no recommended standard therapy for transcription factor EB-renal cell carcinoma. Despite four lines of medical treatment with targeted therapy and one checkpoint inhibitor, all attempts to prolong the patient’s survival failed.

Conclusions

During the course of this unusual disease, we gained insights which, to the best of our knowledge, were unknown before in the expression of the gene signature linked to autophagy. This might in part explain the resistance to conventional targeted therapy acknowledged in our patient.

【 授权许可】

   
2015 Lilleby et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

【 参考文献 】

• [1]Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B et al.. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012; 36(9):1327-38.
• [2]Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA et al.. A gene network regulating lysosomal biogenesis and function. Science. 2009; 325(5939):473-7.
• [3]Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J et al.. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005; 29(2):230-40.
• [4]Lacombe J, Karsenty G, Ferron M. Regulation of lysosome biogenesis and functions in osteoclasts. Cell Cycle. 2013; 12(17):2744-52.
• [5]Malouf GG, Camparo P, Molinie V, Dedet G, Oudard S, Schleiermacher G et al.. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011; 185(1):24-9.
• [6]Pena-Llopis S, Brugarolas J. TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy. Cell Cycle. 2011; 10(23):3987-8.
• [7]Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60.
• [8](GATK resource bundle) [e-mail]. 2015. Ref Type: Internet Communication
• [9](Picard tools)broadinstitute.github.io/picard. 2015. Ref Type: Internet Communication
• [10]McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al.. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303.
• [11]Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al.. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9.
• [12]Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012; 28(14):1811-7.
• [13]Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012; 28(18):i333-9.
• [14]Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L et al.. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-76.
• [15]Al-Lamki RS, Sadler TJ, Wang J, Reid MJ, Warren AY, Movassagh M et al.. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol. 2010; 177(2):943-54.
• [16]Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer. 2009; 124(9):2071-6.
• [17]Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. BioMed Central Full Text
• [18]Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2013; 31(1):46-53.
• [19]Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ et al.. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5.
• [20]Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009; 10(3):R25. BioMed Central Full Text
• [21]Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D et al.. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009; 22(8):1016-22.
• [22]Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M et al.. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res. 2009; 15(7):2507-13.
• [23]Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y et al.. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012; 36(1):35-42.
• [24]Fullgrabe J, Klionsky DJ, Joseph B. The return of the nucleus: transcriptional and epigenetic control of autophagy. Nat Rev Mol Cell Biol. 2014; 15(1):65-74.
• [25]Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP et al.. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014; 11(8):465-75.
• [26]Glasker S, Neumann HPH, Koch CA, Vortmeyer AO. Von Hippel-Lindau syndrome. Endotext. Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, editors. MDText.com, South Dartmouth; 2012.
• [27]Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; 14(1):90-102.
• [28]Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M et al.. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007; 67(3):919-29.
• [29]Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J et al.. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25(8):1603-8.
• [30]Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A et al.. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011; 3(94):94ra70.
• [31]Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fossa SD, Lilleby W. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011; 23(5):339-43.